SWOG clinical trial number
SWOG-8696 (INT-0076) (EST-7186)
Prediction of Recurrence and Therapy Response in the Node Negative Breast Cancer Patient by DNA Flow Cytometry
Abbreviated Title
Prediction of Recurrence and Therapy Response in the Node Negative Breast Cancer Patient by DNA Flow Cytometry
1992
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
DC Allred;R Molina;AK Tandon;SJ Schnitt;KW Gilchrist;CK Osborne;DC Tormey;WL McGuire Human Pathology 23(9):974-979
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an Intergroup study (INT-0076).
LG Dressler;L Eudey ;R Gray;DC Tormey;WL McGuire;KW Gilchrist;CK Osborne;EG Mansour;MD Abeloff JNCI Monographs 11:167-172
HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by presence in in situ carcinoma.
DC Allred;AK Tandon;R Molina;DC Tormey;CK Osborne;KW Gilchrist;EG Monsour;M Abeloff;L Eudey;WL McGuire JCO 10:599-605
1990
DNA flow cytometry measurements are prognostic for the time to recurrence in node negative breast cancer: An Eastern Cooperative Group (ECOG) intergroup study.
LG Dressler;L Eudey;R Gray;DC Tormey;WL McGuire;CK Osborne;KW Gilchrist;EG Mansour;MD Abeloff ASCO 9:22(#81)
Immunocytochemical analysis of HER-2/neu oncogene expression in in situ and invasive breast carcinoma: evaluation of pathological characteristics and biological significance.
DC Allred;R Molina;AK Tandon;CK Osborne;DC Tormey;KW Gilchrist;WL McGuire Modern Pathology 3(1):34